We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
THE LEE COMPANY

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




CSF Glucose Unaltered in Patients With Dementia

By LabMedica International staff writers
Posted on 14 Dec 2022
Print article
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)

A plethora of the pathological processes of many dementia disorders begin several years before the clinical expression of the diseases, and for that reason it is important to discover new biomarkers and methods to detect these processes at an early stage.

Glucose is transported from the blood, through the blood brain barrier (BBB), and into the interstitial space, where it is made available for metabolism by astrocytes and neurons. Normally, there is a close relationship between cerebrospinal fluid (CSF) and plasma glucose concentrations, and the ratio ranges between 0.5 and 0.8, but the ratio may change in different pathological conditions.

Clinical Scientists at the Copenhagen University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues collected CSF and plasma samples from patients referred for diagnostic evaluation. The samples were taken from 446 patients (Alzheimer’s Disease (AD) (n=320), vascular dementia (VaD) (n=64), frontotemporal dementia (FTD) (n=27) and dementia with Lewy bodies (DLB) (n=35)), and 130 healthy controls (HC) (healthy subjects (HS) (n=34), non-demented HS (n=96)).

CSF was collected in 5 mL polypropylene tubes, transported at room temperature, and analyzed on a Radiometer ABL instrument (Radiometer Medical ApS, Brønshøj, Denmark) within an hour after sampling. Plasma was collected in 2 mL Greiner bio-one VACUETTE tubes with Sodium Fluoride/Potassium Oxalate (Greiner, Kremsmünster, Austria), transported at room temperature, and analyzed on a COBAS 8000 instrument (Roche Diagnostics, Indianapolis, IN, USA) within three hours after sampling.

The investigators reported that no significant differences in CSF and plasma glucose levels between the dementia group and HC were found. Furthermore, no significant difference in the CSF/plasma glucose ratio was identified. When investigating CSF glucose, plasma glucose and the CSF/plasma glucose ratio for the different etiologies within the dementia group, no significant differences were found. In addition, no statistically significant differences were found in the relationship between age and CSF glucose, plasma glucose and the CSF/plasma glucose ratio.

The authors concluded that despite severe reductions in the glucose metabolism in the brain of patients with dementia disorders, CSF and plasma glucose levels and the CSF/plasma-glucose ratio do not reflect this hypometabolism, and do not differentiate between dementia of different etiologies. For that reason, it is unlikely that they will have diagnostic potential in a mixed memory clinic setting. The study was published on December 8. 2022 in the journal Clinical Biochemistry.

Related Links:
Copenhagen University Hospital Rigshospitalet
Radiometer Medical
Greiner
Roche Diagnostics

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Supplier
Spinal Fluid Cell Count Control
Spinalscopics

Print article

Channels

Molecular Diagnostics

view channel
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Technology

view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.